Drug Trial Radar · NCT04991311
The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Aug 10, 2021
Primary completion
Feb 2, 2023
Study completion Sep 5, 2023
Sponsor
- Lead sponsor
- Zealand PharmaIndustry
- Sponsor type
- Industry
- First posted
- Aug 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to investigate the long-term effect of glepaglutide on the intestinal absorption, nutritional status of participants with Short Bowel Syndrome (SBS). The trial will also investigate whether glepaglutide is safe during long-term use. All participants in the trial will receive glepaglutide injections. Participants will have 14 visits with the study doctor. At 2 of these, participants will spend 48 hours at the trial site, one visit at the start of the trial and one after 24 weeks of treatment with glepaglutide. At all visits, participants will meet with trial staff and will have blood tests along with other clinical checks and tests done. Participants will be asked about their health and medical history.
Conditions
- Short Bowel Syndrome
Interventions
GlepaglutideDrug
Glepaglutide will be delivered in a single-use autoinjector.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Absorption of Wet Weight/FluidsTime frame: from Week 0 (baseline) to Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rigshospitalet
Copenhagen, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.